<DOC>
	<DOCNO>NCT00413062</DOCNO>
	<brief_summary>The primary purpose study assess contraceptive efficacy , vaginal bleeding pattern ( cycle control ) , general safety acceptability nomegestrol acetate-estradiol ( NOMAC-E2 ) combine oral contraceptive ( COC ) large group woman age 18-50 year .</brief_summary>
	<brief_title>Efficacy Safety Study Combined Oral Contraceptive NOMAC-E2 Compared COC Containing DRSP/EE ( 292002 ) ( P05722 )</brief_title>
	<detailed_description />
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>Sexually active woman , risk pregnancy planning use condom ; Women need contraception willing use oral contraceptive ( OC ) 12 month ( 13 cycle ) ; At least 18 old 50 year age time screen ; Body mass index &gt; =17 &lt; =35 ; Good physical mental health ; Willing give informed consent writing . Contraindications contraceptive steroid In accordance Summary Product Characteristics ( SmPC ) /Package Insert DRSPEE , additional contraindication related antimineralocorticoid activity drospirenone ( condition predispose hyperkalemia ) : Renal insufficiency ; Hepatic dysfunction ; Adrenal insufficiency . An abnormal cervical smear ( i.e . : dysplasia , cervical intraepithelial neoplasia [ CIN ] , squamous intraepithelial lesion [ SIL ] , carcinoma situ , invasive carcinoma ) screening ; Clinically relevant abnormal laboratory result screen judged investigator ; Use injectable hormonal method contraception ; within 6 month injection 3month duration , within 4 month injection 2month duration , within 2 month injection 1month duration ; Before spontaneous menstruation occur follow delivery abortion ; Breastfeeding within 2 month stop breastfeed prior start trial medication ; Present use use within 2 month prior start trial medication follow drug : phenytoin , barbiturate , primidone , carbamazepine , oxcarbazepine , topiramate , felbamate , rifampicin , nelfinavir , ritonavir , griseofulvin , ketoconazole , sex steroid ( pre posttreatment contraceptive method ) herbal remedy contain Hypericum perforatum ( St John 's Wort ) ; Administration investigational drug and/or participation another clinical trial within 2 month prior start trial medication trial period . Subjects diagnosis endometrial biopsy hyperplasia , atypical hyperplasia , carcinoma abnormality judge clinically relevant investigator ( This applicable subject participate endometrial biopsy substudy ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>